Silexion Therapeutics Corp
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31, | December 31 | |
|---|---|---|
| 2026 | 2025 | |
| U.S. dollars in thousands | ||
| Assets | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $2,413 | $5,991 |
| Restricted cash | 27 | 27 |
| Prepaid expenses | 1,529 | 570 |
| Other current assets | 96 | 49 |
| TOTAL CURRENT ASSETS | 4,065 | 6,637 |
| NON-CURRENT ASSETS: | ||
| Restricted cash | 58 | 57 |
| Long-term deposit and other non-current assets | 76 | 84 |
| Property and equipment, net | 23 | 25 |
| Operating lease right-of-use asset | 380 | 412 |
| TOTAL NON-CURRENT ASSETS | 537 | 578 |
| TOTAL ASSETS | $4,602 | $7,215 |
**The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
F - 3
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31, | December 31 | |
|---|---|---|
| 2026 | 2025 | |
| U.S. dollars in thousands | ||
| Liabilities and shareholders’ equity | ||
| CURRENT LIABILITIES: | ||
| Trade payables | $912 | $787 |
| Current maturities of operating lease liability | 185 | 182 |
| Employee related obligations | 560 | 879 |
| Other account payable | 850 | 910 |
| Private warrants to purchase ordinary shares (including $* due to related party, as of March 31, 2026 and December 31, 2025) | * | * |
| Related Party Promissory Note | 1,553 | - |
| TOTAL CURRENT LIABILITIES | 4,060 | 2,758 |
| NON-CURRENT LIABILITIES: | ||
| Long-term operating lease liability | 251 | 286 |
| Related Party Promissory Note | - | 1,568 |
| TOTAL NON-CURRENT LIABILITIES | $251 | $1,854 |
| TOTAL LIABILITIES | $4,311 | $4,612 |
| SHAREHOLDERS' EQUITY: | ||
| Ordinary shares ($0.0135 par value per share, 9,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 3,394,865 and 3,126,651 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively) | 46 | 42 |
| Additional paid-in capital | 58,144 | 57,727 |
| Accumulated deficit | (57,899) | (55,166) |
| TOTAL SHAREHOLDERS' EQUITY | $291 | $2,603 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $4,602 | $7,215 |
**The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
F - 4
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.